Communiqué de presse : Le Dupixent de Sanofi et Regeneron approuvé au Japon pour les enfants de 6 à 11 ans atteints d’asthme bronchique

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Uncontrolled asthma in young children can have potentially lasting impacts such as reduced lung growth and persistent airway obstruction if not treated early

  80% confidence

• Dupixent is the first and only biologic medicine to demonstrate improvement in lung function in this group of young patients in a randomized phase 3 study

  80% confidence

• Dupixent is a fully human monoclonal antibody that inhibits IL-4 and IL-13 signaling pathways and is not an immunosuppressant

  80% confidence

• More than 1.3 million patients are treated with Dupixent worldwide

  80% confidence

• Dupilumab has been studied in more than 60 clinical trials involving more than 10,000 patients with various chronic diseases partly due to type 2 inflammation

  80% confidence

• Dupixent has received regulatory approvals in more than 60 countries for one or more indications

  80% confidence